Review of Bioactive Secondary Metabolites from Marine Bryozoans in the Progress of New Drugs Discovery

Overview

Journal Future Med Chem

Specialties Chemistry
Pharmacy

Date 2018 May 24

PMID 29788787

Citations 12

Authors

Xiang Rong Tian

Hai Feng Tang

Xiao Lin Tian

Jia Jun Hu

Li Li Huang

Kirk R Gustafson

Affiliations

Soon will be listed here.

Abstract

Marine bryozoans play an important role for the discovery of novel bioactive compounds among marine organisms. In this review, we summarize 164 new secondary metabolites including macrocyclic lactones, sterols, alkaloids, sphingolipids and so forth from 24 marine bryozoans in the last two decades. The structural features, bioactivity, structure-activity relationship, mechanism and strategies to address the resupply of these scarce secondary metabolites are discussed. The structural and bioactive diversity of the secondary metabolites from marine bryozoans indicated the possibility of using these compounds, especially bryostatin 1 (1), bryostatin analog (BA1), alkaloids (50, 53, 127-128 and 134-139), sphingolipids sulfates (148 and 149) and sulfur-containing aromatic compound (160), as the starting points for new drug discovery.

Citing Articles

Marine derived macrolide bryostatin 4 inhibits the TGF-β signaling pathway against acute erythroleukemia.

Kou Y, Liu J, Chang Y, Liu L, Sun F, Li Y Cell Oncol (Dordr). 2024; 47(5):1863-1878.

PMID: 39083211 DOI: 10.1007/s13402-024-00968-0.

Recent synthetic strategies of spiro-azetidin-2-one, -pyrrolidine, -indol(one) and -pyran derivatives-a review.

Alshammari M, Aly A, Ahmad A, Brown A, Mohamed A RSC Adv. 2023; 13(46):32786-32823.

PMID: 37942448 PMC: 10628897. DOI: 10.1039/d3ra06054c.

Anti-Inflammatory Effects of Bioactive Compounds from Seaweeds, Bryozoans, Jellyfish, Shellfish and Peanut Worms.

Khursheed M, Ghelani H, Jan R, Adrian T Mar Drugs. 2023; 21(10).

PMID: 37888459 PMC: 10608083. DOI: 10.3390/md21100524.

Rare Caulamidine Hexacyclic Alkaloids from the Marine Ascidian sp.

Tian X, Wang D, Jiang W, Bokesch H, Wilson B, OKeefe B J Nat Prod. 2023; 86(7):1855-1861.

PMID: 37368408 PMC: 10732314. DOI: 10.1021/acs.jnatprod.3c00393.

Anti-Inflammatory Effects of Compounds from Echinoderms.

Ghelani H, Khursheed M, Adrian T, Jan R Mar Drugs. 2022; 20(11).

PMID: 36355016 PMC: 9699147. DOI: 10.3390/md20110693.

References

Milanowski D, Oku N, Cartner L, Bokesch H, Williamson R, Sauri J . Unequivocal determination of caulamidines A and B: application and validation of new tools in the structure elucidation tool box. Chem Sci. 2018; 9(2):307-314. PMC: 5868047. DOI: 10.1039/c7sc01996c. View

Rochfort S, Moore S, Craft C, Martin N, Wagoner R, Wright J . Further studies on the chemistry of the flustra alkaloids from the bryozoan Flustra foliacea. J Nat Prod. 2009; 72(10):1773-81. DOI: 10.1021/np900282j. View

Mizutani K, Sonoda S, Wakita H, Okazaki H, Katoh Y, Chihara T . Effects of exercise and bryostatin-1 on serotonin dynamics after cerebral infarction. Neuroreport. 2016; 27(9):659-64. DOI: 10.1097/WNR.0000000000000592. View

Tian X, Tang H, Li Y, Lin H, Chen X, Ma N . New cytotoxic oxygenated sterols from the marine bryozoan Cryptosula pallasiana. Mar Drugs. 2011; 9(2):162-183. PMC: 3093251. DOI: 10.3390/md9020162. View

Holst P, Anthoni U, Christophersen C, Nielsen P . Marine alkaloids, 15. Two alkaloids, flustramine E and debromoflustramine B, from the marine bryozoan Flustra foliacea. J Nat Prod. 1994; 57(7):997-1000. DOI: 10.1021/np50109a020. View

Davis R, Sykes M, Avery V, Camp D, Quinn R . Convolutamines I and J, antitrypanosomal alkaloids from the bryozoan Amathia tortusa. Bioorg Med Chem. 2011; 19(22):6615-9. DOI: 10.1016/j.bmc.2011.06.006. View

Sudek S, Lopanik N, Waggoner L, Hildebrand M, Anderson C, Liu H . Identification of the putative bryostatin polyketide synthase gene cluster from "Candidatus Endobugula sertula", the uncultivated microbial symbiont of the marine bryozoan Bugula neritina. J Nat Prod. 2007; 70(1):67-74. DOI: 10.1021/np060361d. View

Keck G, Poudel Y, Cummins T, Rudra A, Covel J . Total synthesis of bryostatin 1. J Am Chem Soc. 2010; 133(4):744-7. PMC: 3030632. DOI: 10.1021/ja110198y. View

Yu H, Yang F, Li Y, Gan J, Jiao W, Lin H . Cytotoxic Bryostatin Derivatives from the South China Sea Bryozoan Bugula neritina. J Nat Prod. 2015; 78(5):1169-73. DOI: 10.1021/acs.jnatprod.5b00081. View

10.

Prinsep M . Further pterocellins from the New Zealand marine bryozoan Pterocella vesiculosa. J Nat Prod. 2007; 71(1):134-6. DOI: 10.1021/np070255r. View

11.

Sharp J, Winson M, Porter J . Bryozoan metabolites: an ecological perspective. Nat Prod Rep. 2007; 24(4):659-73. DOI: 10.1039/b617546e. View

12.

Kollar P, Rajchard J, Balounova Z, Pazourek J . Marine natural products: bryostatins in preclinical and clinical studies. Pharm Biol. 2013; 52(2):237-42. DOI: 10.3109/13880209.2013.804100. View

13.

Trost B, Dong G . Total synthesis of bryostatin 16 using atom-economical and chemoselective approaches. Nature. 2008; 456(7221):485-8. PMC: 2728752. DOI: 10.1038/nature07543. View

14.

Gutierrez C, Serrano-Villar S, Madrid-Elena N, Perez-Elias M, Martin M, Barbas C . Bryostatin-1 for latent virus reactivation in HIV-infected patients on antiretroviral therapy. AIDS. 2016; 30(9):1385-92. DOI: 10.1097/QAD.0000000000001064. View

15.

Liu L, Wang W, Huang S, Hong Y, Li G, Lin S . Inhibition of the Ras/Raf interaction and repression of renal cancer xenografts by an enantiomeric iridium(iii) metal-based compound. Chem Sci. 2017; 8(7):4756-4763. PMC: 5603957. DOI: 10.1039/c7sc00311k. View

16.

Irie K, Yanagita R, Nakagawa Y . Challenges to the development of bryostatin-type anticancer drugs based on the activation mechanism of protein kinase Cδ. Med Res Rev. 2012; 32(3):518-35. DOI: 10.1002/med.20220. View

17.

Albada B, Metzler-Nolte N . Highly Potent Antibacterial Organometallic Peptide Conjugates. Acc Chem Res. 2017; 50(10):2510-2518. DOI: 10.1021/acs.accounts.7b00282. View

18.

Blunt J, Copp B, Keyzers R, Munro M, Prinsep M . Marine natural products. Nat Prod Rep. 2017; 34(3):235-294. DOI: 10.1039/c6np00124f. View

19.

Ruan B, Zhu H . The chemistry and biology of the bryostatins: potential PKC inhibitors in clinical development. Curr Med Chem. 2012; 19(16):2652-64. DOI: 10.2174/092986712800493020. View

20.

Zhong H, Lu L, Leung K, Wong C, Peng C, Yan S . An iridium(iii)-based irreversible protein-protein interaction inhibitor of BRD4 as a potent anticancer agent. Chem Sci. 2017; 6(10):5400-5408. PMC: 5510529. DOI: 10.1039/c5sc02321a. View